EPAとDHAの世界市場：種類別、濃度別、形状別、原料別、用途別、地域別 - 成長、動向、予測
EPA & DHA Market - Growth, Trends, and Forecasts (2020-2025)
|発行||Mordor Intelligence LLP||商品コード||754911|
|出版日||ページ情報||英文 100 Pages
|EPAとDHAの世界市場：種類別、濃度別、形状別、原料別、用途別、地域別 - 成長、動向、予測 EPA & DHA Market - Growth, Trends, and Forecasts (2020-2025)|
|出版日: 2020年04月01日||ページ情報: 英文 100 Pages||
Global EPA & DHA market is projected to grow at the CAGR of 9.7% during the forecast period (2020 - 2025).
High Concentrate EPA & DHA Dominated the Market by Concentrate Type
The range of high concentration of omega-3 fatty acids (EPA, DHA) varies from 700-900 mg/g. The high concentrated forms of EPA and DHA are preferred in the pharmaceutical sector for their product formulations. The increasing popularity of omega-3 supplements, especially in the developing markets of Asia-Pacific, Middle East, and Latin America has prompted manufacturers to demand highly concentrated versions of EPA and DHA, owing to their ease of processing and purity parameters. The purity concerns, desire for high effectiveness and bioavailability has also led infant formulae manufacturers to seek for high concentrated forms of EPA and DHA. The other advantage of highly concentrated forms of EPA and DHA is that it reduces the dosage requirements in order to produce desirable results. The supercritical fluid chromatography method is generally used for high concentration omega-3 products as it produces a maximum concentration of up to 99%. SFC enables the industrial production of up to 99% pure fatty acids such as EPA 99%, DHA 99%. The high concentrated forms of EPA and DHA is expected to embark on premiumization aspect of consumer's purchasing behavior.
China Dominated the EPA & DHA Market in Asia-Pacific Region
The strong manufacturing base, increasing middle-class population, disposable income, and health awareness are fueling the consumption of EPA and DHA ingredients in China. The high birth rate and the recent abolition of the one-child policy in China are expected to fuel the demands for DHA-based ingredients for infant nutritional formulae. Infant formulae followed by dietary supplements are two major application areas in the Chinese EPA and DHA market. The dietary supplements sector in China marketplace is expected to emerge as a lucrative application sector for EPA and DHA ingredients amid an increase in discretionary spending.
During the last few years, various global companies have become active in the global EPA and DHA market with tactical acquisitions, mergers, and partnership. For instance: Veramaris (established 50:50 joint venture between DSM & Evonik in 2017) will be producing omega-3 fatty acids (containing rich amount of EPA and DHA) derived from natural marine algae for animal nutrition. Companies, like ADM, BASF SE, Organic technologies, and Novotech Nutraceuticals came up with new products launches. For example, Organic Technologies' launch of two new DHA omega-3 concentrates within its existing product line i.e. a high DHA concentrate and a medium strength DHA (non-tuna) tuna oil alternative.